论文部分内容阅读
作者将23例转移性前列腺癌患者(均有2个以上骨或淋巴转移灶)随机分为两组,黄体生成素释放激素促效药同型物(LHRHa)组有12例患者,均给予LHRHa l1g/日皮下注射;已烯雌酚(DES)组有11例患者,均口服DES 1mg,3次/日。两组均治疗48周。两组患者的肿瘤分级和转移癌分布均相同。DES组治疗前均给予乳腺照射900rad(分3次)。结果:治疗前两组患者的年龄、体重、血红蛋白、肌酐、硷性磷酸酶、前列腺酸性磷酸酶、睾酮、双氢睾酮均无差别。治疗后血清睾酮、双氢睾酮含量变化:LHRHa组治疗1-2周时明显高于治疗前,
The authors randomized 23 patients with metastatic prostate cancer (more than two bone or lymphoid metastases) into two groups, with 12 patients in the LHRHa group, each receiving LHRHa l1g / Day subcutaneous injection; DES group had 11 patients, both oral DES 1mg, 3 times / day. Both groups were treated for 48 weeks. The two groups of patients with tumor grade and metastatic cancer distribution are the same. The DES group received 900rad irradiation (3 times) before treatment. Results: There was no difference in age, weight, hemoglobin, creatinine, alkaline phosphatase, prostatic acid phosphatase, testosterone, dihydrotestosterone in the two groups before treatment. After treatment, serum testosterone, dihydrotestosterone content changes: LHRHa group was significantly higher than the 1-2 weeks before treatment,